

Number	Presentation	Protocol Number
2007		
1	<p>Pasquini M, Ewell M, Stadtmauer E, Bredeson C, Alyea E, Stockerl-Goldstein K, Krishnan A, Sahebi F, Rowley S, Maloney D, Vesole D, Horowitz M, Carter S, Geller N, Giral S. Biologic assignment clinical trials in hematopoietic stem cell transplantation (HSCT) for multiple myeloma: Baseline characteristics by treatment allocation from BMT CTN 0102 according to availability of an HLA-matched sibling donor.</p> <p>Poster presentation: 49th ASH Annual Meeting, Atlanta, GA, December 2007</p>	BMT CTN 0102
2	<p>Wingard J, Carter S, Walsh T, Kurtzberg J, Small T, Gersten I, Mendizabal A, Leather H, Confer D, Baden L, Maziarz R, Stadtmauer E, Bolaños-Meade J, Brown J, DiPersio J, Boeckh M, Marr K. Results of a randomized, double-blind trial of fluconazole (FLU) vs. voriconazole (VORI) for the prevention of invasive fungal infections (IFI) in 600 allogeneic blood and marrow transplant (BMT) patients.</p> <p>Oral presentation: 49th ASH Annual Meeting, Atlanta, GA, December 2007</p>	BMT CTN 0101
2008		
3	<p>Laport G, Bredeson C, Tomblyn MR, Kahl BS, Goodman SA, Ewell M, Klein J, Horowitz MM, Vose JM, Negrin RS. Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with follicular non-Hodgkin lymphoma (FL) beyond first complete response or first partial response.</p> <p>Oral presentation: ASCO Annual Meeting, Chicago, IL, May-June, 2008</p>	BMT CTN 0202
4	<p>Alousi A, Weisdorf D, Logan B, Bolaños-Meade J, Goldstein S, Ho V, Hayes-Lattin B, Wingard J, Horowitz M, Levine J. BMT CTN 0302: A Phase II randomized trial evaluating etanercept, mycophenolate mofetil (MMF), denileukin diftitox, and pentostatin in combination with corticosteroids in 180 patients (pts) with newly diagnosed acute graft vs. host disease (aGVHD).</p> <p>Oral presentation: 50th ASH Annual Meeting, San Francisco, CA, December 2008</p>	BMT CTN 0302
2009		
5	<p>Devine S, Soiffer R, Pasquini M, Carter S, Hari P, Devore S, Stein A, Lazarus H, Linker C, Stadtmauer E, Keever-Taylor C, O'Reilly R. HLA-identical sibling-matched, CD34+ selected, T cell depleted peripheral blood stem cells following myeloablative conditioning for first or second remission acute myeloid leukemia (AML): Results of Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 0303.</p> <p>Oral presentation: 51st ASH Annual Meeting, New Orleans, LA, December 2009</p>	BMT CTN 0303
2010		

Number	Presentation	Protocol Number
6	<p>Pasquini M, Devine S, Mendizabal A, Baden L, Wingard J, Lazarus H, Appelbaum F, Keever-Taylor C, O'Reilly R, Soiffer R. Comparative effectiveness analysis of CD34+ selected, T cell depleted (TCD) HLA-matched sibling grafts on allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia (AML) in complete remission.</p> <p>Poster presentation: BMT Tandem Meetings, Orlando, FL, February 2010</p>	BMT CTN 0303
7	<p>Gurgol C, Foley A, Belt P, Denzen E, Duffy S, Gallagher C, Grodman C, Horowitz M, Confer D, Carter S; on behalf of the BMT CTN Sponsored by NHLBI and NCI. Developing materials for transplant centers to share BMT CTN clinical trial results with their patients, a pilot study.</p> <p>Poster presentation: NCI ASCO Cancer Trials Accrual Symposium, Bethesda, MD, April 2010</p>	Network Abstract
8	<p>Foley A, Horowitz M, Confer D, Carter S; on behalf of the BMT CTN, sponsored by NHLBI and NCI. Development of an accrual assessment tool for BMT CTN transplant trials, a proactive approach.</p> <p>Poster presentation: NCI ASCO Cancer Trials Accrual Symposium, Bethesda, MD, April 2010</p>	Network Abstract
9	<p>Pasquini M, Foley A, Carter S, Confer D, Horowitz M, Gurgol C, Giralt S, Schilsky R, McCarthy P; on behalf of the Cancer and Leukemia Group B and the Blood and Marrow Transplant Clinical Trial Network. Maximizing accrual to transplant trials in multiple myeloma (MM), lessons from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN), Eastern Cooperative Oncology Group (ECOG), and Cancer and Leukemia Group B (CALGB) collaboration.</p> <p>Poster presentation: NCI ASCO Cancer Trials Accrual Symposium, Bethesda, MD, April 2010</p>	BMT CTN 0704 / CALGB 100104 / ECOG 100104
10	<p>Keever-Taylor C, Devine SM, Soiffer RJ, Carter SL, Pasquini MC, Hari P, Stein A, Lazarus HM, Linker C, Goldstein S, O'Reilly RJ; on behalf of the BMT CTN. Characteristics of CD34-enriched products processed at multiple centers using the CliniMacs System - BMT CTN 0303.</p> <p>Oral presentation: International Society for Cellular Therapy 16th Annual Meeting, Philadelphia, PA, May 2010</p>	BMT CTN 0303
11	<p>McCarthy PL, Owzar K, Anderson KC, Hofmeister CC, Hassoun H, Hurd DD, Stadtmauer EA, Giralt S, Hars V, Linker CA. Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM): CALGB 100104.</p> <p>Oral presentation: ASCO Annual Meeting, Chicago, IL, June 2010</p>	BMT CTN 0704 / CALGB 100104 / ECOG 100104

Number	Presentation	Protocol Number
12	<p>McCarthy PL, Owzar K, Anderson K, Hofmeister CC, Hurd DD, Hassoun H, Giralt S, Stadtmauer EA, Richardson PG, Weisdorf DJ, Vij R, Moreb JS, Callander N, Van Besien K, Gentile T, Isola L, Maziarz RT, Gabriel DA, Bashey A, Landau H, Martin T, Qazilbash MH, Levitan D, McClune B, Hars V, Postiglione J, Jiang C, Bennett E, Barry SS, Bressler L, Kelly M, Sexton M, Rosenbaum C, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Linker C. Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous hematopoietic stem cell transplantation (AHSCT) for multiple myeloma: CALGB 100104.</p> <p>Oral presentation: 52nd ASH Annual Meeting, Orlando, FL, December 2010</p>	BMT CTN 0704 / CALGB 100104 / ECOG 100104
13	<p>Krishnan A, Pasquini MC, Ewell M, Stadtmauer EA, Alyea EP, Antin JH, Comenzo RL, Goodman S, Hari P, Negrin R, Qazilbash MH, Rowley SD, Sahebi F, Somlo G, Vesole DH, Vogl DT, Weisdorf DJ, Geller N, Horowitz MM, Giralt S, Maloney DG. Tandem autologous hematopoietic stem cell transplants (AuHCT) with or without maintenance therapy (auto-auto) versus single AuHCT followed by HLA matched sibling non-myeloablative allogeneic HCT (auto-allo) for patients with standard risk (SR) multiple myeloma (MM): Results from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0102 trial.</p> <p>Oral presentation: 52nd ASH Annual Meeting, Orlando, FL, December 2010</p>	BMT CTN 0102
14	<p>Stadtmauer EA, Krishnan A, Pasquini MC, Ewell M, Alyea EP, Antin JH, Castro-Malaspina H, Kassim AA, Negrin R, Qazilbash MH, Rizzo JD, Rowley SD, Sahebi F, Somlo G, Vesole DH, Vogl DT, Weisdorf DJ, Geller N, Horowitz MM, Maloney DG, Giralt S. Tandem autologous stem cell transplants (auto-auto) with or without maintenance therapy versus single autologous transplant followed by HLA-matched sibling non-myeloablative allogeneic stem cell transplant (auto-allo) for patients (pts) with high risk (HR) multiple myeloma: Results from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0102 Trial.</p> <p>Oral presentation: 52nd ASH Annual Meeting, Orlando, FL, December 2010</p>	BMT CTN 0102
15	<p>Switzer GE, Harrington D, Haagenson MD, Drexler R, Foley A, Confer DL, Bishop M, Anderlini P, Rowley SD, Leitman S, Anasetti C, Wingard JR. Health-related quality-of-life among adult unrelated stem cell donors: A Blood and Marrow Transplant Clinical Trials Network (BMT CTN) randomized trial of marrow versus PBSC donation.</p> <p>Oral presentation: 52nd ASH Annual Meeting, Orlando, FL, December 2010</p>	BMT CTN 0201
2011		
16	<p>Fuchs EJ, Wu J, Carter S, Brunstein C, Costa L, Wingard J, Jagasia M, D'Elia J, Eapen M, O'Donnell PV. Phase II trial of non-myeloablative conditioning and partially HLA-mismatched (HLA-haploidentical) bone marrow transplantation (BMT) for patients with hematologic malignancies: Results of Blood and Marrow Transplant Clinical Trials Network (BMT CTN) protocol 0603.</p> <p>Oral presentation: BMT Tandem Meetings, Honolulu, HI, February 2011</p> <p>*Received a Best Abstract Award</p>	BMT CTN 0603

Number	Presentation	Protocol Number
17	<p>Brunstein CG, Carter S, Fuchs EJ, Karanes C, Devine S, Cutler C, Ballen KK, Thompson J, O'Donnell PV, Eapen M. Phase II trial of non-myeloablative conditioning (NST) double umbilical cord blood transplantation (DUCBT) from unrelated donors in patients with hematologic malignancies: Results of Blood and Marrow Transplant Clinical Trials Network (BMT CTN) protocol 0604.</p> <p>Oral presentation: BMT Tandem Meetings, Honolulu, HI, February 2011 *Received a Best Abstract Award</p>	BMT CTN 0604
18	<p>Levine JE, Logan BR, Wu J, Alousi AM, Bolaños-Meade J, Ho VT, Weisdorf DJ, Paczesny S. GVHD biomarkers measured during treatment independently predict response to therapy and survival: A Blood and Marrow Transplant Clinical Trials Network study.</p> <p>Oral presentation: 37th EBMT Annual Meeting, Paris, France, April 2011</p>	BMT CTN 0302
19	<p>McCarthy P, Owzar K, Anderson K, Hofmeister C, Richardson P, Hassoun H, Stadtmauer E, Giralt S, Hurd D, Hars V, Jiang C, Postiglione J, Bressler L, Devine S, Linker C. Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM): CALGB ECOG BMT CTN 100104.</p> <p>Oral presentation: 13th International Myeloma Workshop, Paris, France, May 2011</p>	BMT CTN 0704 / CALGB 100104 / ECOG 100104
20	<p>Krishnan A, Pasquini M, Logan B, Stadtmauer EA, Alyea III E, Antin J, Comenzo R, Goodman S, Hari P, Negrin R, Qazilbash M, Rowley S, Sahebi F, Somlo G, Vesole D, Vogl D, Weisdorf D, Wu J, Geller N, Horowitz MM, Giralt S, Maloney D. Tandem autologous HCT (auto-auto) versus single autologous HCT followed by HLA matched sibling non-myeloablative allogeneic HCT (auto-allo) for patients with standard risk multiple myeloma: Results from the BMT-CTN 0102 trial.</p> <p>Poster presentation: 13th International Myeloma Workshop, Paris, France, May 2011</p>	BMT CTN 0102
21	<p>Hari P, Pasquini M, Logan B, Stadtmauer E, Krishnan A, Howard A, Alvi S, Harding S, Carter S, Rajkumar V, Alyea III E, Qazilbash M, Laport G, Maloney D, Giralt S, Vesole D. Immunoglobulin free light chain (FLC) and heavy chain/light chain (HLC) assays – comparison with electrophoretic responses in multiple myeloma (MM).</p> <p>Poster presentation: 53rd ASH Annual Meeting, San Diego, CA, December 2011</p>	BMT CTN 0102
22	<p>Anasetti C, Logan B, Lee SJ, Waller EK, Weisdorf D, Wingard JR, Cutler C, Westervelt P, Woolfrey A, Couban S, Johnston L, Maziarz R, Pulsipher M, Anderlini P, Bensinger W, Leitman S, Rowley SD, Carter SL, Horowitz MM, Confer DL. Increased incidence of chronic graft-versus-host disease (GVHD) and no survival advantage with filgrastim-mobilized peripheral blood stem cells (PBSC) compared to bone marrow (BM) transplants from unrelated donors: Results of Blood and Marrow Transplant Clinical Trials Network (BMT CTN) protocol 0201, a Phase III, prospective, randomized trial.</p> <p>Oral presentation (plenary session): 53rd ASH Annual Meeting, San Diego, CA, December 2011</p>	BMT CTN 0201

Number	Presentation	Protocol Number
23	<p>Waller EK, Harris WAC, Devine S, Porter DL, Mineishi S, McCarty JM, Gonzalez CE, Spitzer TR, Krijanovski OI, Linenberger ML, Woolfrey A, Howard A, Gurgol C, Logan BR, Confer DL, Anasetti C. Larger numbers of donor naïve CD8+ T-cells and plasmacytoid dendritic cell precursors in allogeneic BM grafts from unrelated donors are associated with improved survival: Results from BMT CTN 0201.</p> <p>Oral presentation: 53rd ASH Annual Meeting, San Diego, CA, December 2011</p>	BMT CTN 0201
24	<p>Tolar J, Deeg HJ, Arai S, Horwitz M, Antin JH, McCarty J, Adams R, Eapen M, Ewell M, Leifer E, Gersten I, Carter SL, Horowitz MM, Confer D, Nakamura R, Pulsipher MA, DiFronzo N, Anderlini P. Fludarabine-based conditioning for allogeneic marrow transplantation from unrelated donors in severe aplastic anemia (SAA): Serious and unexpected adverse events in pre-defined cyclophosphamide (CY) dose levels.</p> <p>Poster presentation: 53rd ASH Annual Meeting, San Diego, CA, December 2011</p>	BMT CTN 0301
25	<p>Vose JM, Carter SL, Burns L, Ayala E, Press O, Moskowitz C, Stadtmauer E, Mineishi S, Ambinder R, Fenske T, Horowitz M, Tomblyn M. Randomized Phase III trial of 131Iodine-Tositumomab (Bexxar)/Carmustine, Etoposide, Cytarabine, Melphalan (BEAM) versus Rituximab/BEAM and autologous stem cell transplantation for relapsed diffuse large B-cell lymphoma (DLBCL): No difference in progression-free (PFS) or overall survival (OS).</p> <p>Oral presentation: 53rd ASH Annual Meeting, San Diego, CA, December 2011</p>	BMT CTN 0401
26	<p>Spelley R, Denzen E, Burton Santibáñez M, Moore H, Foley A, Gersten I, Gurgol C, Horowitz M, Majhail N, Murphy E. Informed consent: Improving the form and the process.</p> <p>Oral presentation: Public Responsibility in Medicine and Research (PRIM&R) Advancing Ethical Research Conference, National Harbor, MD, December 2011</p>	Network Abstract
2012		
27	<p>Waller EK, Harris WA, Devine S, Porter DL, Ferrara J, McCarty JM, Gonzalez CE, Spitzer TR, Krijanovski OI, Howard A, Gurgol C, Logan BR, Confer DL, Anasetti C. Grade III-IV acute GVHD and treatment-related mortality are reduced among recipients of larger numbers of donor naïve CD8+ T-cells and plasmacytoid dendritic cell precursors in allogeneic BM grafts from unrelated donors: Results from BMT CTN 0201.</p> <p>Oral presentation: 38th EBMT Annual Meeting, Geneva, Switzerland, April 2012</p>	BMT CTN 0201
28	<p>Anderlini P, Tolar J, Deeg HJ, Arai S, Horwitz M, Antin JH, McCarty JM, Adams RH, Ewell M, Leifer E, Gersten I, Carter SL, Horowitz MM, Confer DL, Nakamura R, Pulsipher M, DiFronzo NL, Eapen M. Fludarabine-based conditioning for allogeneic marrow transplantation from unrelated donors in severe aplastic anaemia: Serious and unexpected adverse events in pre-defined cyclophosphamide dose levels.</p> <p>Poster presentation: 38th EBMT Annual Meeting, Geneva, Switzerland, April 2012</p>	BMT CTN 0301
29	<p>Crann ME, Mendizabal AM, Gersten ID, Carter SL. Adverse event reporting for hematopoietic stem cell transplant studies.</p> <p>Poster presentation: Society for Clinical Trials 33rd Annual Meeting, Miami, FL, May 2012</p>	Network Abstract

Number	Presentation	Protocol Number
30	Anasetti C, Logan B, Lee SJ, Waller EK, Weisdorf D, Wingard JR, Cutler C, Westervelt P, Woolfrey A, Couban S, Johnston L, Maziarz R, Pulsipher M, Anderlini P, Bensinger W, Leitman S, Rowley SD, Carter SL, Horowitz MM, Confer DL. Increased incidence of chronic graft-versus-host disease (GVHD) and no survival advantage with filgrastim-mobilized peripheral blood stem cells (PBSC) compared to bone marrow transplants from unrelated donors: Results of Blood and Marrow Transplant Clinical Trials Network (BMT CTN) protocol #0201, a Phase III, prospective, randomized trial. Oral presentation: ASCO Annual Meeting (ASCO/ASH Joint Session), Chicago, IL, June 2012	BMT CTN 0201
31	Cutler C, Logan BR, Nakamura R, Johnston L, Choi SW, Porter DL, Hogan WJ, Pasquini MC, MacMillan ML, Wingard JR, Waller EK, Grupp SA, McCarthy PL, Wu J, Hu Z, Carter SL, Horowitz MM, Antin JH. Tacrolimus/sirolimus vs. tacrolimus/methotrexate for graft-vs.-host disease prophylaxis after HLA-matched, related donor hematopoietic stem cell transplantation: Results of Bone Marrow Transplant Clinical Trials Network 0402. Oral presentation: 54th ASH Annual Meeting, Atlanta, GA, December 2012	BMT CTN 0402
32	Wagner JE, Eapen M, Carter SL, Haut P, Peres E, Schultz K, Thompson J, Wall D, Kurtzberg J. No survival advantage after double umbilical cord blood (UCB) compared to single UCB transplant in children with hematological malignancy: Results of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0501) randomized trial. Oral presentation: 54th ASH Annual Meeting, Atlanta, GA, December 2012	BMT CTN 0501
33	Devine SM, Owzar K, Blum W, DeAngelo DJ, Stone RM, Hsu JW, Champlin R, Chen YA, Vij R, Slack JL, Soiffer RJ, Larson RA, Shea TC, Hars V, Bennett E, Spangle S, Giralt SA, Carter SL, Horowitz MM, Linker C, Alyea III EP. A Phase II study of allogeneic transplantation for older patients with AML in first complete remission using a reduced intensity conditioning regimen: Results from CALGB 100103/BMT CTN 0502. Oral presentation: 54th ASH Annual Meeting, Atlanta, GA, December 2012	BMT CTN 0502 / CALGB 100103
2013		
34	Yanik G, Ho VT, Horowitz MM, Weisdorf DJ, Logan BR, Wu J, Soiffer RJ, Wingard JR, Levine JE, Ferrara JL, Giralt SA, White E, Carter SL, DiFronzo N, Cooke KR. Randomized, double blind, placebo-controlled trial of a TNF inhibitor (etanercept) for the treatment of idiopathic pneumonia syndrome (IPS) after allogeneic stem cell transplant (SCT), a Blood and Marrow Transplant Clinical Trials Network (BMTCTN) study. Oral presentation: BMT Tandem Meetings, Salt Lake City, UT, February 2013	BMT CTN 0403
35	Kurtzberg J, Carter SL, Mendizabal A, Wall DA, Schultz KR, Kernan NA, Eapen M, Wagner JE. Superior survival after single unit umbilical cord blood transplantation (UCBT) in children with hematological malignancies treated on Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0501 relative to the cord blood transplantation (COBLT). Oral presentation: BMT Tandem Meetings, Salt Lake City, UT, February 2013	BMT CTN 0501

Number	Presentation	Protocol Number
36	<p>Bolaños-Meade J, Logan BR, Alousi AM, Antin JH, Barowski K, Carter SL, Hexner EO, Horowitz MM, Levine JE, MacMillan ML, Martin PJ, Nakamura R, Pasquini MC, Weisdorf DJ, Westervelt P, Ho VT. A multi-center, randomized, double blind, Phase III clinical trial comparing steroids/placebo vs. steroids/mycophenolate mofetil as initial therapy for acute graft-versus-host disease. Blood and Marrow Transplant Clinical Trials Network Study 0802.</p> <p>Oral presentation: BMT Tandem Meetings, Salt Lake City, UT, February 2013</p>	BMT CTN 0802
37	<p>McCarthy P, Owzar K, Hofmeister C, Richardson P, Hassoun H, Stadtmauer E, Giralt S, Hurd D, Qazilbash M, McClune B, Pasquini M, Hars V, Jiang C, Postiglione J, Kelly M, Bressler L, Devine S, Anderson K, Linker C. Analysis of overall survival (OS) in the context of cross-over from placebo to lenalidomide and the incidence of second primary malignancies (SPM) in the Phase III study of lenalidomide versus placebo maintenance therapy following autologous stem cell transplant (ASCT) for multiple myeloma (MM), CALGB (Alliance) ECOG, BMT CTN 100104.</p> <p>Oral presentation: 14th International Myeloma Workshop, Kyoto, Japan, April 2013</p>	BMT CTN 0704 / CALGB 100104 / ECOG 100104
38	<p>Lee SJ, Le-Rademacher JL, Jim H, Syrjala KL, Wingard JL, Logan BR, Wu J, Majhail NS, Wood WA, Rizzo JD, Geller NL, Kitko CL, Faber Jr. EA, Abidi MH, Slater SE, Horowitz MM, Jacobsen P. Exercise and stress management training for patients undergoing autologous or allogeneic hematopoietic cell transplantation. Results from Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902.</p> <p>Oral presentation: 55th ASH Annual Meeting, New Orleans, LA, December 2013</p>	BMT CTN 0902
2014		
39	<p>Levine JE, Braun TM, Harris AC, Holler E, Taylor A, Miller H, Magenau J, Weisdorf DJ, Ho VT, Bolaños-Meade J, Alousi AM, Ferrara JL. A new Ann Arbor grading system uses biomarkers to risk stratify patients for non relapse mortality at the onset of acute graft versus host disease.</p> <p>Oral presentation: 40th EBMT Annual Meeting, Milan, Italy, March-April 2014</p>	BMT CTN 0302 / 0802
40	<p>Mendizabal AM, Pasquini MC, Logan BR, Gersten ID, DiFronzo NL, Wagner EL, Merritt WD, Wu RS, Confer DL, Horowitz MM. Leveraging resources to design, conduct, and analyze hematopoietic stem cell transplant clinical trials: The ongoing collaboration between the Center for International Blood and Marrow Transplant Research and the Blood and Marrow Transplant Clinical Trials Network.</p> <p>Oral presentation: Society for Clinical Trials 35th Annual Meeting, Philadelphia, PA, May 2014</p>	Network Abstract
41	<p>Hope WW, Walsh TJ, Goodwin J, Peloquin C, Howard A, Kurtzberg J, Mendizabal A, Confer D, Bulitta J, Neely M, Baden L, Wingard J. Relationship between voriconazole concentrations and the probability of breakthrough fungal infections.</p> <p>Poster presentation: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, September 2014</p>	BMT CTN 0101

Number	Presentation	Protocol Number
42	<p>Anderlini P, Wu J, Deeg J, Gersten I, Ewell M, Tolar J, Antin JH, Arai S, Horowitz ME, McCarty JM, Nakamura R, Pulsipher MA, Adams RH, Leifer E, Carter SL, DiFronzo NL, Horowitz MM, Confer DL, Eapen M. Optimized cyclophosphamide (CY) dosing in combination with fludarabine, TBI and ATG as conditioning for unrelated donor bone marrow transplantation (BMT) in severe aplastic anemia (SAA): A Phase I/II study from the Blood and Marrow Transplant Clinical Trials Network (BMTCTN).</p> <p>Oral presentation: 56th ASH Annual Meeting, San Francisco, CA, December 2014</p>	BMT CTN 0301
43	<p>Holtan SG, Verneris MR, Schultz KR, Newell L, Meyers G, He FC, DeFor TE, MacMillan ML, Cooley SA, Panoskaltis-Mortari A, Weisdorf DJ. Circulating angiogenic factors as biomarkers of acute GVHD onset and response to therapy: Repair and regeneration versus endothelial damage and inflammation.</p> <p>Poster presentation: 56th ASH Annual Meeting, San Francisco, CA, December 2014</p>	BMT CTN 0302 / 0802
44	<p>Levine JE, Braun TM, Harris AC, Holler E, Taylor A, Miller HK, Magenau JM, Weisdorf DJ, Ho VT, Bolaños-Meade J, Alousi AM, Ferrara JL. A biomarker algorithm defines onset grades of acute graft-vs-host disease with distinct non-relapse mortality.</p> <p>Oral presentation: 56th ASH Annual Meeting, San Francisco, CA, December 2014</p>	BMT CTN 0302 / 0802
45	<p>Laport GG, Wu J, Logan BR, Bachanova V, Hosing CM, Fenske TS, Longo WL, Devine SM, Nademanee AP, Gersten I, Horowitz MM, Lazarus HM, Riches ML. Reduced intensity conditioning (RIC) with rituximab yields excellent outcomes after allogeneic hematopoietic cell transplantation (alloHCT) for relapsed follicular lymphoma (FL): A Phase II multicenter trial from the Blood and Marrow Transplant Network (BMT CTN 0701).</p> <p>Oral presentation: 56th ASH Annual Meeting, San Francisco, CA, December 2014</p>	BMT CTN 0701
46	<p>Smith EP, Li H, Friedberg JW, Constine L, Rimsza LM, Laport GG, Popplewell LL, Maloney DG, Leblanc M, Forman SJ, Fisher RI, Stiff PJ. SWOG S0410 / BMT CTN 0703: A Phase II trial of tandem autologous stem cell transplantation (AHCT) for patients with primary progressive or recurrent Hodgkin lymphoma (HL).</p> <p>Oral presentation: 56th ASH Annual Meeting, San Francisco, CA, December 2014</p>	BMT CTN 0703
47	<p>Alvarnas J, Le-Rademacher J, Wang Y, Little RF, Akpek G, Ayala E, Devine S, Kaplan L, Noy A, Popat U, Thompson J, Horowitz MM, Mendizabal A, Navarro WH, Ambinder R. Autologous hematopoietic stem cell transplantation (AHCT) in patients with chemotherapy-sensitive, relapsed / refractory (CSRR) human immunodeficiency virus (HIV)-associated lymphoma (HAL): Results from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0803) / AIDS Malignancy Consortium (AMC-071) trial.</p> <p>Oral presentation: 56th ASH Annual Meeting, San Francisco, CA, December 2014</p>	BMT CTN 0803
48	<p>Wood WA, Le-Rademacher J, Fei M, Logan BR, Syrjala KL, Majhail NS, Wingard JR, Abidi MH, Geller NL, Wu J, Rizzo JD, Faber Jr EA., Jim H, Jacobsen P, Horowitz MM, Lee SJ. Patient-reported quality of life is an independent predictor of survival after allogeneic hematopoietic cell transplantation: A secondary analysis from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902.</p> <p>Oral presentation: 56th ASH Annual Meeting, San Francisco, CA, December 2014</p>	BMT CTN 0902

Number	Presentation	Protocol Number
2015		
49	Holtan S, Verneris MR, Schultz KR, Newell LF, Meyers G, He F, DeFor TE, MacMillan ML, Cooley S, Blazar BR, Panoskaltis-Mortari A, Weisdorf DJ. Prognostic impact of follistatin in acute graft-versus-host disease: Results from BMT CTN 0302 and 0802. Oral presentation: BMT Tandem Meetings, San Diego, CA, February 2015	BMT CTN 0302 / 0802
50	Young JH, Logan BR, Wu J, Wingard JR, Weisdorf DJ, Mudrick C, Knust K, Horowitz MM, Confer DL, Anasetti C. More infections with transplantation of bone marrow, versus peripheral-blood stem cells, from unrelated donors. Oral presentation: BMT Tandem Meetings, San Diego, CA, February 2015	BMT CTN 0201
51	Moore HK, Denzen EM, Idossa L, Murphy EA, Foley A, Gersten ID, Majhail NS, Spellecy R, Horowitz MM. Easy-to-read informed consent (ETRIC) forms for multi-center hematopoietic cell transplant clinical trials (BMT CTN 1205). Poster presentation: Institute for Healthcare Advancement's 14th Annual Health Literacy Conference, Irvine, CA, May 2015	BMT CTN 1205
52	Holstein SA, Owzar K, Richardson PG, Jiang C, Hofmeister CC, Hassoun H, Hurd DD, Stadtmauer EA, Giralt S, Devine SM, Hars V, Postiglione JR, Weisdorf DJ, Vij R, Moreb JS, Callander NS, Martin TG, Shea TC, Anderson KC, McCarthy PL. Updated analysis of CALGB / ECOG / BMT CTN 100104: Lenalidomide (Len) vs. placebo (PBO) maintenance therapy after single autologous stem cell transplant (ASCT) for multiple myeloma (MM). Poster presentation: ASCO Annual Meeting, Chicago, IL, May-June 2015	BMT CTN 0704 / CALGB 100104 / ECOG 100104
53	D'Souza A, Pasquini MC, Logan BR, Giralt SA, Krishnan A, Antin J, Howard A, Horowitz MM, Goodman S, Laport GG, Qazilbash M, Mendizabal AM, Sahebi F, Weisdorf D, Vesole D, Stadtmauer EA, Maloney D, Hari P. Heavy light chain ratio normalization allows identification of electrophoretic non-complete response patients with improved outcomes: A long term follow up update for BMT CTN 0102 correlative study. Poster presentation: 20th Congress of European Hematology Association, Vienna, Austria, June 2015	BMT CTN 0102
54	Knight JM, Martens M, Syrjala KL, Le-Rademacher J, Logan BR, Lee SJ, Jacobsen PB, Wood WA, Jim H, Wingard JR, Horowitz MM, Majhail NS, Abidi MH, Geller NL, Fei M, Wu J, Rizzo JD. Pre-transplant health-related quality of life factors as predictors of outcomes following hematopoietic cell transplantation: A study from the BMT CTN 0902 trial. Oral presentation: IPOS / APOS World Congress on Psycho-Oncology, Washington DC, July-August 2015	BMT CTN 0902
55	Syrjala KL, Sutton SK, Yi JC, Jim H, Knight JM, Wood WA, Jacobsen PB, Majhail NS, Abidi MH, Wingard JR, Horowitz MM, Rizzo JD, Le-Rademacher J, Wu J, Lee SJ. Cancer and treatment distress measurement over time in a multicenter cohort of hematopoietic cell transplantation (HCT) recipients (BMT CTN 0902). Oral presentation: IPOS / APOS World Congress on Psycho-Oncology, Washington DC, July-August 2015	BMT CTN 0902

Number	Presentation	Protocol Number
56	<p>Holstein SA, Owzar K, Richardson PG, Jiang C, Hofmeister CC, Hassoun H, Hurd DD, Stadtmauer EA, Giralt S, Devine SM, Hars V, Postiglione JR, Weisdorf DJ, Vij R, Moreb JS, Callander NS, Pasquini MC, Martin TG, Shea TC, Anderson KC, McCarthy PL. Analysis of second primary malignancies (SPMs) in CALGB (Alliance) / ECOG / BMT CTN 100104.</p> <p>Poster presentation: 15th International Myeloma Workshop, Rome, Italy, September 2015</p>	BMT CTN 0704 / CALGB 100104 / ECOG 100104
57	<p>Scott BL, Pasquini MC, Logan BR, Wu J, Devine S, Porter DL, Maziarz RT, Warlick E, Fernandez HF, Alyea EP, Hamadani M, Bashey A, Giralt SA, Leifer E, Geller N, Le-Rademacher J, Mendizabal AM, Horowitz MM, Deeg HJ, Horwitz ME. Results of a Phase III randomized, multi-center study of allogeneic stem cell transplantation after high versus reduced intensity conditioning in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML): Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0901.</p> <p>Oral presentation: 57th ASH Annual Meeting, Orlando, FL, December 2015</p> <p>* Late Breaking Abstract</p>	BMT CTN 0901
58	<p>Ravandi F, Othus M, O'Brien S, Forman SJ, Ha CS, Wong JY, Tallman MS, Paietta E, Racevskis J, Uy GL, Borate U, Kebriaei P, Kingsbury L, Kantarjian HM, Radich JP, Erba HP, Appelbaum FR. Multi-center US intergroup study of intensive chemotherapy plus dasatinib followed by allogeneic stem cell transplant in patients with Philadelphia chromosome positive acute lymphoblastic leukemia younger than 60.</p> <p>Oral presentation: 57th ASH Annual Meeting, Orlando, FL, December 2015</p>	BMT CTN 0805
59	<p>Shenoy S, Eapen M, Wu J, Walters MC, Levine JE, Logan BR, Gersten ID, Kamani NR. A multicenter Phase II trial of unrelated donor reduced intensity bone marrow transplantation for children with severe sickle cell disease (SCURT): Results of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0601) study.</p> <p>Oral presentation: 57th ASH Annual Meeting, Orlando, FL, December 2015</p>	BMT CTN 0601
60	<p>Lee SJ, Logan BR, Westervelt P, Cutler CS, Woolfrey AE, Khan S, Waller EK, Maziarz RT, Wu J, Shaw BE, Confer DL, Horowitz MM, Anasetti C. 5 year results of BMT CTN 0201: Unrelated donor bone marrow is associated with better psychological well-being and less burdensome chronic GVHD symptoms than peripheral blood.</p> <p>Oral presentation: 57th ASH Annual Meeting, Orlando, FL, December 2015</p>	BMT CTN 0201
2016		
61	<p>Carpenter PA, Logan BR, Lee SJ, Weisdorf DJ, Johnston L, Costa LJ, Kitko CL, Bolaños-Meade J, Alousi AM, Horowitz MM, Abhyankar S, Waller EK, Mendizabal A, Wang Y, Lazaryan A, Carter SL, Nemecek ER, Pavletic SZ, Cutler CS, Arora M. Prednisone (PDN) / sirolimus (SRL) compared to PDN / SRL / calcineurin inhibitor (CNI) as treatment for chronic graft-versus-host-disease (cGVHD): A randomized Phase II study from the Blood and Marrow Transplant Clinical Trials Network.</p> <p>Oral presentation: BMT Tandem Meetings, Honolulu, HI, February 2016</p>	BMT CTN 0801

Number	Presentation	Protocol Number
62	<p>Scott BL, Pasquini MC, Logan BR, Wu J, Devine S, Porter DL, Maziarz RT, Warlick E, Fernandez HF, Alyea EP, Hamadani M, Bashey A, Giral SA, Leifer E, Geller N, Le-Rademacher J, Mendizabal AM, Horowitz MM, Deeg HJ, Horwitz ME. Results of a Phase III randomized, multi-center study of allogeneic stem cell transplantation after high versus reduced intensity conditioning in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML): Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0901.</p> <p>Oral presentation: BMT Tandem Meetings, Honolulu, HI, February 2016 * Special Invited Abstract: BMT CTN 0901 Randomized Trial</p>	BMT CTN 0901
63	<p>Newell LF, Verneris MR, Panoskaltis-Mortari A, Defor TE, Blazar BR, Cutler CS, Antin JH, MacMillan ML, Weisdorf DJ, Holtan S. Angiogenic factors, inflammation, and outcomes in myeloablative allogeneic hematopoietic cell transplantation: A biomarker analysis of GVHD prophylaxis in Blood and Marrow Transplant Clinical Trials Network protocol (BMT CTN) 0402.</p> <p>Oral presentation: BMT Tandem Meetings, Honolulu, HI, February 2016</p>	BMT CTN 0402
64	<p>Shenoy S, Eapen M, Wu J, Walters MC, Levine JE, Logan BR, Gersten ID, Kamani NR. Results of the Blood and Marrow Transplant Clinical Trials Network study BMT CTN 0601: SCURT - a multicenter Phase II trial of unrelated donor reduced intensity bone marrow transplantation (BMT) for children with severe sickle cell disease.</p> <p>Oral presentation: BMT Tandem Meetings, Honolulu, HI, February 2016</p>	BMT CTN 0601
65	<p>Maziarz RT, Lazarus HM, Riches ML, Mudrick C, Mendizabal A. BMT CTN trials: A rich source for regimen related toxicity assessments in the modern era.</p> <p>Poster presentation: BMT Tandem Meetings, Honolulu, HI, February 2016</p>	Network Abstract
66	<p>Anderlini P, Wu J, Deeg HJ, Gersten ID, Ewell M, Tolar J, Antin J, Arai S, Horwitz M, McCarty J, Nakamura R, Pulsipher M, Adams R, Leifer E, DiFronzo N, Horowitz MM, Confer DL, Eapen M. Cyclophosphamide (CY) conditioning in patients with severe aplastic anaemia (SAA) given unrelated marrow transplantation: Final results of a Phase 1-2 dose de-escalation study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0301).</p> <p>Poster presentation: 42nd EBMT Annual Meeting, Valencia, Spain, April 2016</p>	BMT CTN 0301
67	<p>Burns LJ, Logan BR, Chitphakdithai P, Miller J, Drexler R, Spellman S, Switzer G, Wingard J, Anasetti C, Confer DL. Faster recovery of unrelated donors of peripheral blood stem cells (PBSC) vs bone marrow (BM): A prespecified analysis from BMT CTN 0201.</p> <p>Poster presentation: 42nd EBMT Annual Meeting, Valencia, Spain, April 2016</p>	BMT CTN 0201
68	<p>Attal M, Palumbo A, Holstein SA, Lauwers-Cances V, Petrucci MT, Richardson PG, Hulin C, Tosi P, Anderson KC, Caillot D, Magarotto V, Moreau P, Marit G, Yu Z, McCarthy PL. Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): A meta-analysis (MA) of overall survival (OS).</p> <p>Oral abstract presentation: ASCO Annual Meeting, Chicago, IL, June 2016</p>	BMT CTN 0704 / CALGB 100104 / ECOG 100104

Number	Presentation	Protocol Number
69	<p>Knight JM, Martens M, Syrjala KL, Le-Rademacher J, Logan BR, Lee SJ, Jacobsen PB, Wood WA, Jim H, Wingard JR, Horowitz MM, Majhail NS, Abidi MH, Geller NL, Fei M, Wu J, Rizzo JD. Psychosocial and socioeconomic status as predictors of outcomes following hematopoietic stem cell transplantation: An ancillary study from the BMT CTN 0902 randomized controlled trial (RCT).</p> <p>Poster presentation: PsychoNeuroImmunology Research Society's 23rd Annual Scientific Meeting, Brighton, United Kingdom, June 2016</p>	BMT CTN 0902
70	<p>McCarthy PL, Palumbo A, Holstein SA, Lauwers-Cances V, Petrucci MT, Richardson PG, Hulin C, Tosi P, Anderson KC, Caillot D, Magarotto V, Moreau P, Marit G, Yu Z, Attal M. A meta-analysis of overall survival in patients with multiple myeloma treated with lenalidomide maintenance after high-dose melphalan and autologous stem cell transplant.</p> <p>Oral presentation: 21st Congress of the European Hematology Association, Copenhagen Denmark, June 2016</p>	BMT CTN 0704 / CALGB 100104 / ECOG 100104
71	<p>Eapen M, Kurtzberg J, Zhang M, Mendizabal AM, Chang KW, Duval M, Fei M, Neudorf S, De Oliveira SN, Wall DA, Schultz KR, Horowitz MM, Wagner JE. Umbilical cord blood (UCB) transplantation in children with acute leukemia: Impact of conditioning regimen on transplant outcomes.</p> <p>Oral presentation: 58th ASH Annual Meeting, San Diego, CA, December 2016</p>	BMT CTN 0501
72	<p>Newell LF, DeFor TE, Cutler CS, Verneris MR, Blazar BR, Antin JH, Howard A, Wu J, MacMillan ML, Panoskaltis-Mortari A, Weisdorf DJ, Holtan SG. Follistatin and endoglin: Potential biomarkers of endothelial damage and non-relapse mortality after myeloablative allogeneic hematopoietic cell transplantation in Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0402.</p> <p>Oral presentation: 58th ASH Annual Meeting, San Diego, CA, December 2016</p>	BMT CTN 0402
73	<p>Makowski M, Ahmed E, Schlotter S, Pearson R, Kitzler R, Alvarnas JC, Le-Rademacher J, Wang Y, Little RF, Akpek G, Ayala E, Devine SM, Kaplan LD, Noy A, Popat UR, Hsu JW, Morris LE, Thompson J, Horowitz MM, Mendizabal AM, Levine AM, Krishnan A, Hade E, Hofmeister CC, Forman SJ, Navarro WH, Ambinder RF, Lozanski G, Baiocchi RA. Evaluation of immune recovery following autologous hematopoietic cell transplantation in HIV-related lymphoma: Results of the BMT CTN 0803/AMC 071 Trial.</p> <p>Poster presentation: 58th ASH Annual Meeting, San Diego, CA, December 2016</p>	BMT CTN 0803

Number	Presentation	Protocol Number
74	<p>Stadtmauer EA, Pasquini MC, Blackwell B, Knust K, Bashey A, Devine SM, Efebera YA, Ganguly S, Gasparetto Cristina, Geller N, Giralt SA, Hari P, Horowitz MM, Koreth J, Landau H, McCarthy PL, McClune B, Nelson C, Qazilbash MH, Shah N, Vesole DH, Vij R, Vogl DT, Somlo G, Krishnan A. Comparison of autologous hematopoietic cell transplant (autoHCT), bortezomib, lenalidomide (Len) and dexamethasone (RVD) consolidation with len maintenance (ACM), tandem autoHCT with len maintenance (TAM) and autoHCT with len maintenance (AM) for up-front treatment of patients with multiple myeloma (MM): Primary results from the randomized Phase III trial of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0702 – StaMINA Trial).</p> <p>Oral presentation: 58th ASH Annual Meeting, San Diego, CA, December 2016</p>	BMT CTN 0702
2017		
75	<p>Newell LF, DeFor TE, Cutler CS, Verneris MR, Blazar BR, Antin JH, Howard A, Wu J, MacMillan ML, Panoskaltis-Mortari A, Weisdorf DJ, Holtan SG. Follistatin and endoglin: Potential biomarkers of endothelial damage and non-relapse mortality after myeloablative allogeneic hematopoietic cell transplantation in Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0402.</p> <p>Oral presentation: BMT Tandem Meetings, Orlando, FL, February 2017</p>	BMT CTN 0402
76	<p>Pidala JA, Martens M, Carreras J, Anasetti C, Cutler CS, Lee SJ, Antin JH, Horowitz MM, Logan BR. Multi-state modeling identifies determinants of successful immune suppression discontinuation: Secondary analysis of BMT CTN 0201 and 0402 trials.</p> <p>Oral presentation: BMT Tandem Meetings, Orlando, FL, February 2017</p>	BMT CTN 0201 / 0402
77	<p>Khera N, Mau L, Denzen EM, Houg K, Lee SJ, Horowitz MM, Burns LJ. Understanding physicians' perspectives about translating research into clinical practice: Example of Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0201 results.</p> <p>Oral presentation: BMT Tandem Meetings, Orlando, FL, February 2017</p>	BMT CTN 0201
78	<p>Krishnan A, Pasquini M, Blackwell B, Knust K, Bashey A, Devine S, Efebera Y, Ganguly S, Gasparetti C, Geller N, Giralt S, Hari P, Horowitz M, Koreth J, Landau H, McCarthy P, McClune B, Nelson C, Qazilbash M, Shah N, Vesole D, Vij R, Vogl DT, Somlo G, Stadtmauer E. Post autologous transplant (autoHCT) therapies in high risk MM. Subgroup analysis of Phase III BMT CTN 0702-STaMINA: AutoHCT followed by lenalidomide maintenance (Len) (AM) versus auto HCT and len and bortezomib (BZ) and dexamethasone consolidation len maintenance (ACM) vs tandem autoHCT len maintenance.</p> <p>Oral presentation: 16th International Myeloma Workshop, New Delhi, India, March 2017</p>	BMT CTN 0702
79	<p>McCarthy P, Holstein S, Petrucci MT, Richardson P, Hulin C, Tosi P, Bringhen S, Musto P, Anderson KC, Caillot D, Gay F, Moreau P, Marit G, Jung S, Yu Z, Winograd B, Knight R, Palumbo A, Attal M. Lenalidomide (LEN) maintenance following high-dose melphalan and autologous stem cell transplant (ASCT) in patients (Pts) with newly diagnosed multiple myeloma (MM): A meta-analysis of overall survival (OS).</p> <p>Oral presentation: 16th International Myeloma Workshop, New Delhi, India, March 2017</p>	BMT CTN 0704 / CALGB 100104 / ECOG 100104

Number	Presentation	Protocol Number
80	<p>McCarthy PL, Holstein SA, Jung S-H, Cooper M, Gibson C, Winograd B, Richardson P. Overall survival (OS) and progression-free survival (PFS) adjusted for treatment crossover in the CALGB/ECOG 100104 (Alliance) study of lenalidomide (LEN) versus placebo (PBO) maintenance after stem cell transplant (SCT) for patients with newly diagnosed multiple myeloma.</p> <p>Oral presentation: 16th International Myeloma Workshop, New Delhi, India, March 2017</p>	BMT CTN 0704 / CALGB 100104 / ECOG 100104
81	<p>Nelson C, O'Brien K, Mendizabal A, Gersten I, Uhl L, Chung D, Shah N, Avigan D, Pasquini M. Translation of a single-center cellular therapy manufacturing approach to a multi-center, center-specific manufacturing platform: The experience of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol #1401.</p> <p>Poster presentation: Society for Clinical Trials 38th Annual Meeting, Liverpool, United Kingdom, May 2017</p>	BMT CTN 1401
82	<p>Nelson C, O'Brien K, Mendizabal A, Gersten I, Uhl L, Chung D, Shah N, Avigan D, Pasquini M. Development and management of a multi-center, center-specific cellular therapy manufacturing approach: The experience of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol #1401.</p> <p>Poster presentation: International Society for Cellular Therapy 25th Annual Meeting, London, United Kingdom, May 2017</p>	BMT CTN 1401
83	<p>Somlo G, Pasquini MC, Blackwell B, Devine SM, Ganguly S, Efebera Y, Giralt S, Hari P, Koreth J, Landau HJ, McClune BL, McCarthy PL, Shah N, Vesole DH, Vij R, Vogl DT, Krishnan AY, Stadtmauer EA, Geller N. Response status as predictor of survival after autologous hematopoietic cell transplant (AHCT), without or with consolidation (with bortezomib, lenalidomide (Len) and dexamethasone) and len maintenance (AM vs. ACM) versus tandem AHCT and len maintenance (TAM) for up-front treatment of patients (pts) with multiple myeloma (MM). BMT CTN 0702-STaMINA (NCT01109004)</p> <p>Poster presentation: ASCO Annual Meeting, Chicago IL, June 2017</p>	BMT CTN 0702
84	<p>Ambinder RF, Wu J, Logan B, Durand C, Shields R, Popat UR, Little RF, McMahon D, Mellors JW, Ayala E, Kaplan LD, Noy A, Howard A, Forman SJ, Mendizabal AM, Horowitz MM, Navarro WH, Alvarnas JC. Allogeneic hematopoietic cell transplant (alloHCT) for hematologic malignancies in human immunodeficiency virus infected (HIV) patients (pts): Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0903) / AIDS malignancy consortium (AMC-080) trial.</p> <p>Oral presentation: ASCO Annual Meeting, Chicago, IL, June 2017</p>	BMT CTN 0903
85	<p>Logan B, Brazauskas R, Fraser R. Randomized Phase II trials vs. single arm Phase II trials with a registry control in rare diseases.</p> <p>Oral presentation: International Chinese Statistical Association Meeting, Chicago, IL, June 2017</p>	Network Abstract
86	<p>Logan B, Brazauskas R, Fraser R. Phase II trials and the use of registry controls.</p> <p>Oral presentation: American Statistical Association Joint Statistical Meetings, Baltimore, MD, July 2017</p>	Network Abstract

Number	Presentation	Protocol Number
87	<p>Martens M, Logan B. Group sequential tests of treatment effect on survival and cumulative incidence at a fixed time point.</p> <p>Oral presentation: Biostatistics in the Modern Computing Era conference, Medical College of Wisconsin, Milwaukee, WI, September 2017</p>	BMT CTN 0402
88	<p>Fernando SM, Logan BR, Fei M, Lee SJ, Confer D, Howard A, Chandrakasan S, Giver CR, Anasetti C, Waller EK. Day 100 levels of blood immune cells are prognostic biomarkers for allogeneic hematopoietic stem cell transplant outcomes: Results from BMT CTN 0201.</p> <p>Oral presentation: 59th ASH Annual Meeting, Atlanta, GA, December 2017</p>	BMT CTN 0201
89	<p>Holtan SG, DeFor TE, Pidala J, Khera N, Lee SJ, Howard A, Wu J, Bolaños-Meade J, Ho VT, Alousi AM, Inamoto Y, Chen G, Arora M, Palmer J, Flowers ME, Cutler CS, Lukez A, Arai S, Lazaryan A, Newell LF, Jagasia M, Pusic I, Mayer SA, Wood WA, Renteria A, Hogan WJ, Hexner E, Ayuk FA, Holler E, Efebera YA, Reantragoon R, Duong H, Yanik G, Ferrara JL, Levine JE, Blazar B, Panoskaltis-Mortari A, Weisdorf DJ, MacMillan ML. Amphiregulin improves stratification of the refined Minnesota acute graft-versus-host disease risk score: Results from BMT CTN 0302/0802.</p> <p>Oral presentation: 59th ASH Annual Meeting, Atlanta, GA, December 2017</p>	BMT CTN 0302 / 0802
90	<p>Waller EK, Logan BR, Fei M, Howard A, Wingard JR, Anasetti C, Giver CR. Efficacy of early post-transplant vaccination using a prime and boost strategy is independent of a prior history of GvHD: Results from BMT CTN0201.</p> <p>Poster presentation: 59th ASH Annual Meeting, Atlanta, GA, December 2017</p>	BMT CTN 0201
91	<p>Majhail NS, Tarima S, Denzen E, Moore H, Abhyankar S, Dawson P, Foley A, Gersten ID, Horwitz ME, Idossa L, Joffe S, Kamani N, King R, Lazaryan A, Morris LE, Horowitz MM, Spelley R. Easy-to-read informed consent (ETRIC) form for hematopoietic cell transplantation (HCT) clinical trials: Results from Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 1205 study.</p> <p>Poster presentation: 59th ASH Annual Meeting, Atlanta, GA, December 2017</p>	BMT CTN 1205
2018		
92	<p>Bolaños-Meade J, Reshef R, Fraser R, Fei M, Abhyankar S, Al-Kadhimi Z, Alousi AM, Antin JH, Bickett K, Damon LE, Efebera YA, Geller N, Giralt SA, Hari P, Holtan SG, Horowitz MM, Jacobsohn DA, Jones RJ, Liesveld J, Logan BR, MacMillan ML, Mielcarek MB, Noel P, Pidala JA, Porter DL, Weisdorf DJ, Wu J, Pasquini MC, Koreth J. Novel approaches for graft-versus-host disease (GvHD) prophylaxis: Primary results of progress I multicenter trial of matched allogeneic hematopoietic cell transplantation (alloHCT) using reduced intensity conditioning (RIC) BMT CTN 1203.</p> <p>Oral presentation: BMT Tandem Meetings, Salt Lake City, UT, February 2018</p> <p>*Late Breaking Abstract</p>	BMT CTN 1203

Number	Presentation	Protocol Number
93	Levis MJ, Hamadani M, Logan B, Rosales M, Perl AE, Devine SM, Bahceci E, Chen Y. A Phase 3, trial of gilteritinib a maintenance therapy after allogeneic hematopoietic stem cell transplantation in patients with FLT3-ITD+ AML. Poster presentation: ASCO Annual Meeting, Chicago, IL, June 2018	BMT CTN 1506
94	Goptu M, Kim HT, Howard A, Choi SW, Soiffer RJ, Antin JH, Ritz J, Cutler CS. A post-hoc analysis for BMT CTN 0402 comparing immune reconstitution between tacrolimus / methotrexate (Tac/MTX) and sirolimus / tacrolimus (Sir/Tac) arms. Poster presentation: ASH Annual Meeting, San Diego, CA, December 2018	BMT CTN 0402
2019		
95	Pidala JA, Hamadani M, Dawson P, Alousi AM, Jagasia M, Efebera YA, Chhabra S, Pusic I, Holtan SG, Ferrara J, Levine JE, Anasetti C, Pritchard T, Martens M, Horowitz MM, MacMillan ML. Sirolimus vs. prednisone as initial systemic therapy for Minnesota Standard Risk (MN-SR), Ann Arbor 1/2 acute graft-vs-host disease (GVHD): Primary results of the multi-center randomized Phase II BMT CTN 1501 trial. Oral presentation: TCT Meetings, Houston, TX, February 2019	BMT CTN 1501
96	Reshef R, Saber W, Bolaños-Meade J, Chen GL, Chen Y, Ho VT, Ponce DM, Nakamura R, Martens MJ, Hansen JA, Levine JE. Acute GVHD diagnosis and adjudication in a multicenter trial – a report from the BMT CTN 1202 biorepository study. Oral presentation: TCT Meetings, Houston, TX, February 2019	BMT CTN 1202
97	Hahn TE, Wallace PK, Fraser R, Fei M, Tario JD, Howard A, Zhang Y, Blackwell B, Brunstein CG, Efebera YA, Geller N, Giralt SA, Hari P, Knust K, Koreth, J, Krishnan A, Landau H, Shah N, Somlo G, Stadtmauer EA, Vogl DT, Vesole DH, McCarty PL, Pasquini MC. Minimal residual disease (MRD) assessment before and after autologous hematopoietic cell transplantation (AutoHCT) and maintenance for multiple myeloma (MM): Results of the prognostic immunophenotyping for myeloma response (PRIMeR) study. Oral presentation: TCT Meetings, Houston, TX, February 2019 * Best Abstract Award	BMT CTN 0702
98	Krupski MC, Allen C, Howard A, Neumeier L, Lane A, Pulsipher MA, Mehta PA, Davies SM, Marsh RA. Alemtuzumab controls acute GVHD and mixed chimerism risks in pediatric patients with HLH undergoing stem cell transplantation: A correlative biology study from the CTN 1204 RICHI trial. Poster presentation: 2019 TCT Meetings, Houston, TX, February 2019	BMT CTN 1204
99	Hourigan CS, Dillon LW, Gui G, Logan BR, Fei M, Ghannam J, Li Y, Licon A, Alyea EP, Bashey A, Deeg HJ, Devine SM, Fernandez HF, Giralt S, Hamadani M, Howard A, Maziarz RT, Porter DL, Scott BL, Warlick ED, Pasquini MC, Horwitz ME. Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia with Genomic Evidence of Residual Disease. Oral presentation: 2019 EHA Meetings, Amsterdam, Netherlands, June 2019 *Late-Breaking Submission	BMT CTN 0901

Number	Presentation	Protocol Number
100	<p>Costa L, Iacobelli S, Pasquini M, Modi R, Giaccone L, Blade J, Schonland S, Evangelista A, Perez-Simon J, Hari P, Brown E, Giralt S, Patriarca F, Stadtmauer E, Rosinol L, Krishnan A, Gahrton G, Bruno B. 259 Tandem Autologous-Autologous Vs. Autologous-Allogeneic Transplantation for Newly Diagnosed Multiple Myeloma: Pooled Analysis of 1,338 Patients from Four Trials with Long-Term Follow up.</p> <p>Oral presentation: 2019 ASH Meeting, San Diego, CA, December 2019</p>	BMT CTN 0102
101	<p>Eapen M, Neuberg D, Mendizabal A, Stevenson K, Antin J, DiFronzo N, El Rassi F, Lulla , Waller E, Garrison J, Smith S, Sullivan K, Walters M, Krishnamurti. A Phase II Trial to Compare Allogeneic Transplant Vs. Standard of care for severe sickle cell disease: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 1503</p> <p>Poster Presentation: 2019 ASH Meeting, San Diego, CA, December 2019</p>	BMT CTN 1503
102	<p>Levis M, Hamadani M, Logan B, Rosales M, Delgado D, Bahceci E, Devine S, Horowitz M, Chen Yi-Chen. BMT CTN Protocol 1506: A Phase 3 Trial of Gilteritinib As Maintenance Therapy after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with <i>FLT3-ITD</i>⁺ AML</p> <p>Poster Presentation: 2019 ASH Meeting, San Diego, CA, December 2019</p>	BMT CTN 1506
103	<p>Vasu S, Bejanyan N, Devine S, Hexner E, Krakow E, Logan B, Luznik L, Ragon B, Barrett E, Shan J, Champlin R. BMT CTN 1803: Haploidentical Natural Killer Cells (CSTD002) to Prevent Post-Transplant Relapse in AML and MDS(NK-REALM)</p> <p>Poster Presentation: 2019 ASH Meeting, San Diego, CA, December 2019</p>	BMT CTN 1803
104	<p>Shindiapina P, Pietrzak M, Seweryn M, McLaughlin E, Zhang X, Makowski M, Lyberger J, Chang H, Hassan Ahmed E, Prouty A, Pearson R, Kitzler R, Le-Rademacher J, Little R, Akpek G, Ayala E, Devine S, Noy A, Kaplan L, Popat U, Hsu J, Morris L, Mendizabal A, Hofmeister C, Wachsmann W, Forman S, Navarro W, Alvarnas J, Ambinder R, Behbehani G, Lozanski G, Baiocchi R. Comparative Analysis of Immune Reconstitution in HIV-Positive Recipients of Allogeneic and Autologous Stem Cell Transplant on the BMT CTN 0903/AMC-080 and BMT CTN 0803/AMC-071 Trials</p> <p>Poster Presentation: 2019 ASH Meeting, San Diego, CA, December 2019</p>	BMT CTN 0803 / 0903
105	<p>Holtan S, Bhatt A, Fraser R, Perales M, Kean L, Saber W, Hamadani M, Logan B, Bolanos-Meade J. Making Progress in Graft-Versus-Host Disease Prophylaxis and Microbiome Analysis in the Blood and Marrow Transplant Clinical Trials Network: Progress III (1703)/MI-Immune (1801)</p> <p>Poster Presentation: 2019 ASH Meeting, San Diego, CA, December 2019</p>	BMT CTN 1703 / 1801
106	<p>Kassim A, Walters M, Eapen M, Allison B, Mendizabal A, Brodsky R, DeBaun M. Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients with Symptomatic Sickle Cell Disease: BMT CTN Protocol 1507</p> <p>Oral Presentation: 2019 ASH Meeting, San Diego, CA, December 2019</p>	BMT CTN 1507
2020		

Number	Presentation	Protocol Number
107	<p>Scott B. Long-Term Follow up of BMT CTN 0901, a Randomized Phase III Trial Comparing Myeloablative (MAC) to Reduced Intensity Conditioning (RIC) Prior to Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia (AML) or Myelodysplasia (MDS) (MAvRIC Trial)</p> <p>Oral Presentation: 2020 TCT Meeting, Orlando, FL, February 2020</p>	BMT CTN 0901
108	<p>Vasu S, Bejanyan N, Devine S, Hexner E, Krakow E, Logan B, Luznik L, Ragon B, Barrett E, Shan J, Champlin R. BMT CTN 1803: Haploidentical Natural Killer Cells (CSTD002) to Prevent Post-Transplant Relapse in AML and MDS(NK-REALM)</p> <p>Poster presentation: 2020 TCT Meeting, Orlando, FL, February 2020</p>	BMT CTN 1803
109	<p>Shindiapina P, Pietrzak M, Seweryn M, McLaughlin E, Zhang X, Makowski M, Lyberger J, Chang H, Hassan Ahmed E, Prouty A, Pearson R, Kitzler R, Le-Rademacher J, Little R, Akpek G, Ayala E, Devine S, Noy A, Kaplan L, Popat U, Hsu J, Morris L, Mendizabal A, Hofmeister C, Wachsmann W, Forman S, Navarro W, Alvarnas J, Ambinder R, Behbehani G, Lozanski G, Baiocchi R. Comparative Analysis of Immune Reconstitution in HIV-Positive Recipients of Allogeneic and Autologous Stem Cell Transplant on the BMT CTN 0903/AMC-080 and BMT CTN 0803/AMC-071 Trials</p> <p>Poster presentation: 2020 TCT Meeting, Orlando, FL, February 2020</p>	BMT CTN 0803 / 0903
110	<p>Brunstein C, O'Donnel P, Eapen M, Logan B, Antin J, Dawson P, Devine S, DiFronzo N, Horowitz M, Horowitz M, Leifer E, Karanes C, Magenau J, McGuirk J, Morris L, Rezvani A, Jones R, Fuchs E. Results of Blood and Marrow Transplant Clinical Trials Network Protocol 1101 a Multicenter Phase III Randomized Trial of Transplantation of Double Umbilical Cord Blood Vs. HLA-Haploidentical -Related Bone Marrow for Hematologic Malignancy</p> <p>Oral Presentation: 2020 TCT Meeting, Orlando, FL, February 2020</p> <p>*Late Breaking Abstract</p>	BMT CTN 1101
111	<p>Avigan D, Shah N, Logan B, Zhu J, Bisharat L, Callander N, Chodon T, Dhakal B, Efebera Y, Geller N, Hematti P, Herman M, Lazarus H, McKenna D, Nelson C, Nooka A, O'Brien K, O'Donnell L, Rapoport A, Rosenblatt J, Soiffer R, Stroopinsky D, Torka P, Uhl L, Waller E, Wu J, Young J, Pasquini M, Chung D. Evaluation of Tumor Vaccine Generation in a Phase II Multicenter Trial of Single Autologous Hematopoietic Cell Transplant (AutoHCT) Followed By Lenalidomide Maintenance for Multiple Myeloma (MM) with or without Vaccination with Dendritic Cell/ Myeloma Fusions (DC/MM fusion vaccine): Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 1401.</p> <p>Oral Presentation: 2020 TCT Meeting, Orlando, FL, February 2020</p>	BMT CTN 1401
112	<p>Farhadfar N, Burns L, Mupfudze T, Shaw B, Bollard C, Devine S, DiFronzo N, Horowitz M, Jones R, Murthy H, Wingard J, Lee S. Hematopoietic Cell Transplantation (HCT) Predictions for the Year 2023.</p> <p>Poster presentation: 2020 TCT Meeting, Orlando, FL, February 2020</p>	Network Abstract

Number	Presentation	Protocol Number
113	<p>Hari P, Pasquini MC, Stadtmauer EA, Fraser R, Fei M, Devine SM, Efebera YA, Geller N, Horowitz MM, Koreth J, Landau HJ, McCarthy PL, Qazilbash MH, Shah N, Vesole DH, Vogl DT, Somlo G, Krishnan AY, Giralt S. Long-term follow-up of BMT CTN 0702 (STaMINA) of postautologous hematopoietic cell transplantation (autoHCT) strategies in the upfront treatment of multiple myeloma (MM).</p> <p>Oral presentation: ASCO Annual Meeting, Virtual, May 2020</p>	BMT CTN 07LT (0702)
114	<p>Brunstein C, O'Donnell PV, Eapen M, Logan B, Antin JH, Dawson P, Devine S, DiFronzo N, Horowitz MM, Horwitz ME, Karanes C, Leifer E, Magenau JM, McGuirk JP, Morris LE, Rezvani AR, Jones RJ, Fuchs EJ. Results of Blood and Marrow Transplant Clinical Trials Network protocol 1101 a multicenter Phase III randomized trial of transplantation of double umbilical cord blood vs. HLA-haploidentical-related bone marrow for hematologic malignancy.</p> <p>Oral Presentation: 46th EBMT Annual Meeting, Virtual, August-September 2020</p>	BMT CTN 1101
115	<p>Dillon L, Gui G, Logan B, Fei M, Ghannam J, Li Y, Licon A, Alyea E, Bashey A, Deeg HJ, Devine S, Fernandez HF, Giralt S, Hamadani M, Howard A, Maziarz R, Porter, Scott B, Warlick E, Pasquini M, Horwitz M, Hourigan C. Impact of conditioning intensity and genomics on relapse after allogeneic transplantation for patients with myelodysplastic syndrome.</p> <p>Oral Presentation: European Hematology Association Annual Congress, Virtual, November 2020</p>	BMT CTN 1901
116	<p>Vasu S, Bejanyan N, Devine SM, Hexner EO, Logan B, Luznik L, Ragon B, Sandler A, Krakow EF, Fitzgerald M, Tracey L, Champlin ER. BMT CTN 1803: Haploidentical natural killer cells (CSTD002) to prevent post-transplant relapse in AML and MDS (NK-REALM).</p> <p>Poster Presentation: 62nd ASH Annual Meeting, Virtual, December 2020</p>	BMT CTN 1803
117	<p>Nakamura R, Saber W, Martens MJ, Ramirez A, Scott BL, Oran B, Leifer E, Tamari R, Mishra A, Maziarz RT, McGuirk JP, Westervelt P, Vasu S, Patnaik MM, Kamble R, Forman SJ, Sekeres MA, Appelbaum FR, Mendizabal AM, Logan B, Horowitz MM, Cutler C. A multi-center biologic assignment trial comparing reduced intensity allogeneic hematopoietic cell transplantation to hypomethylating therapy or best supportive care in patients aged 50-75 with advanced myelodysplastic syndrome: Blood and Marrow Transplant Clinical Trials Network study 1102.</p> <p>Oral Presentation: 62nd ASH Annual Meeting, Virtual, December 2020</p>	BMT CTN 1102
2021		
118	<p>Vasu S, Bejanyan N, Devine SM, Hexner EO, Logan B, Luznik L, Ragon B, Sandler A, Krakow EF, Fitzgerald M, Tracey L, Champlin ER. BMT CTN 1803: Haploidentical natural killer cells (CSTD002) to prevent post-transplant relapse in AML and MDS (NK-REALM).</p> <p>Poster Presentation: TCT Meetings of ASTCT and CIBMTR, Virtual, February 2021</p>	BMT CTN 1803

Number	Presentation	Protocol Number
119	<p>Nakamura R, Saber W, Martens M, Ramirez A, Scott BL, Oran B, Leifer E, Tamari R, Mishra A, Maziarz RT, McGuirk JP, Westervelt P, Vasu S, Patnaik MM, Kamble RT, Forman SJ, Sekeres MA, Appelbaum FR, Mendizabal A, Logan B, Horowitz MM, Cutler C. A multi-center biologic assignment trial comparing reduced intensity allogeneic hematopoietic cell transplantation to hypomethylating therapy or best supportive care in patients aged 50-75 with advanced myelodysplastic syndrome: Blood and Marrow Transplant Clinical Trials Network Study 1102.</p> <p>Oral Presentation: TCT Meetings of ASTCT and CIBMTR, Virtual, February 2021</p> <p>*Best Abstract Award</p>	BMT CTN 1102
120	<p>Putta S, Young B, Ho VT, Reshef R, Nakamura R, Strouse C, Perales M, Howard A, Pine P, Shi J, Zhang P, Levine JE, Saber W. Prognostic biomarker signature for hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) in recipients of myeloablative (MA) allogeneic hematopoietic cell transplantation (HCT).</p> <p>Oral Presentation: TCT Meetings of ASTCT and CIBMTR, Virtual, February 2021</p>	BMT CTN 1202
121	<p>Pasquini MC, Luznik L, Logan B, Soiffer R, Wu J, Devine SM, Geller N, Giralt SA, Heslop HE, Horowitz MM, Litzow MR, Mendizabal A, Muffly L, Nemecek ER, O'Donnell LC, Palencia R, Schetelig J, Shune L, Solomon SR, Vasu S, Ho VT, Perales M. Calcineurin inhibitor-free graft-versus-host disease (GVHD) prophylaxis in hematopoietic cell transplantation (HCT) with myeloablative conditioning regimens (MAC) and HLA-matched donors: Results of the BMT CTN 1301 PROGRESS II trial.</p> <p>Oral Presentation: TCT Meetings of ASTCT and CIBMTR, Virtual, February 2021</p> <p>*Late Breaking Abstract</p>	BMT CTN 1301
122	<p>Luznik L, Pasquini MC, Logan B, Soiffer R, Wu J, Devine SM, Geller N, Giralt SA, Heslop HE, Horowitz MM, Litzow MR, Mendizabal A, Muffly L, Nemecek ER, O'Donnell LC, Palencia R, Schetelig J, Shune L, Solomon SR, Vasu S, Ho VT, Perales M. Calcineurin inhibitor-free graft-versus-host disease (GVHD) prophylaxis in hematopoietic cell transplantation (HCT) with myeloablative conditioning regimens (MAC) and HLA-matched donors: Results of the BMT CTN 1301.</p> <p>Oral Presentation : 47th EBMT Annual Meeting, Virtual, March 2021</p> <p>*Presidential Symposium Plenary Session</p>	BMT CTN 1301
123	<p>Putta S, Young B, Ho VT, Reshef R, Nakamura R, Strouse C, Perales M, Howard A, Pine P, Shi J, Zhang P, Levine JE, Saber W. Prognostic biomarker signature for hepatic veno-occlusive disease / sinusoidal obstruction syndrome (VOD/SOS) in recipients of myeloablative (MA) allogeneic haematopoietic cell transplantation (HCT).</p> <p>Oral Presentation: 47th EBMT Annual Meeting, Virtual, March 2021</p>	BMT CTN 1202
124	<p>Vasu S, Bejanyan N, Devine S, Hexner E, Logan B, Luznik L, Ragon B, Sandler A, Krakow E, Fitzgerald M, Tracey L, Champlin R. BMT CTN 1803: Haploidentical natural killer cells (K-NK002) to prevent post-transplant relapse in AML and MDS (NK-REALM).</p> <p>Poster Presentation: 47th EBMT Annual Meeting, Virtual, March 2021</p>	BMT CTN 1803

Number	Presentation	Protocol Number
125	<p>Dispenzieri A, Krishnan AY, Arendt B, Dasari S, Efebera YA, Geller N, Giralt S, Hahn T, Kohlhagen MC, Landau HJ, Hari P, Pasquini MC, Qazilbash MH, McCarthy PL, Shah N, Vesole DH, Vogl DT, Wallace PK, Stadtmauer EA, Murray DL (2021). Mass-fix versus standard methods to predict for PFS and OS among multiple myeloma patients participating on the stamina trial.</p> <p>Poster Presentation: ASCO Annual Meeting, Chicago, IL, June 2021</p>	BMT CTN 0702
126	<p>Nishihori T, Bashir Q, Pasquini MC, Martens M, Wu J, Alsina M, Efebera YA, Gasparetto C, Geller N, Giralt S, Koreth J, McCarthy PL, Scott EC, Stadtmauer EA, Vesole DH, & Hari P. The results of multicenter Phase II, double-blind placebo-controlled trial of maintenance ixazomib after allogeneic hematopoietic cell transplantation (alloHCT) for high-risk multiple myeloma (MM) from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 1302).</p> <p>Oral Presentation: ASCO Annual Meeting, Chicago, IL, June 2021</p>	BMT CTN 1302
127	<p>D'Souza A, Brazauskas R, Stadtmauer EA, Pasquini MC, Hari P, Bashey A, Callander N, Devine S, Efebera Y, Ganguly S, Gasparetto C, Geller N, Horowitz MM, Koreth J, Landau H, Brunstein C, McCarthy P, Qazilbash MH, Giralt S, Krishnan A, Flynn KE. Trajectories of symptom and quality of life (QOL) recovery after autologous stem cell transplantation (ASCT) in multiple myeloma (MM): Secondary analysis of BMT CTN 0702 trial.</p> <p>Oral Presentation: ISOQOL 28th Annual Meeting, Virtual, June 2021</p>	BMT CTN 0702
128	<p>Geerlinks AV, Scull B, Krupski C, Fleischmann R, Pulsipher MA, Eapen M, Connelly JA, Bollard CM, Pai SY, Duncan CN, Kean LS, Baker KS, Burroughs LS, Andolina JR, Jordan MB, Man TK, Allen CE, and Marsh R. Peri-transplant alemtuzumab levels predict risk of secondary graft failure and inversely impact CXCL9 levels after RIC HCT (A correlative biology study to BMT-CTN 1204 RICHI).</p> <p>Oral Presentation: Histiocyte Society 37th Annual Meeting, Virtual October 2021</p>	BMT CTN 1204
129	<p>Farhadfar N, Mandava M, Bo-Subait, S, Ahn KW, Stefanski H, Hsu JW, Panch S, Coffey D, Anasetti C, Pulsipher M, Shaw BE, Wingard JR, Switzer G. The impact of pre-apheresis health related quality of life on peripheral blood progenitor cell yield and donor's health and outcome: Secondary analysis of RDSafe and BMT CTN 0201</p> <p>Poster Presentation: 63rd ASH Annual Meeting, Atlanta, GA December 2021</p>	BMT CTN 0201
130	<p>Brunstein CG, O'Donnell PV, Logan B, Dawson P, Costa L, Cutler C, Craig M, Hogan W, Horowitz MM, Horwitz ME, Karanes C, Magenau JM, Malone A, McCarty J, McGuirk JP, Morris LE, Rezvani AR, Salit R, Vasu S, Eapen M, Fuchs EJ. Impact of center experience with donor type on outcomes: A secondary analysis, Blood and Marrow Transplant Clinical Trials Network 1101.</p> <p>Poster Presentation: 63rd ASH Annual Meeting, Atlanta, GA, December 2021</p>	BMT CNT 1101
131	<p>Cusatis R, Martens M, Nakamura R, Cutler C, Saber W, Lee SJ, Logan B, Shaw BE, Horowitz, MM, Flynn, KE. Health-related quality of life in a biologic assignment trial of reduced intensity hematopoietic cell transplantation based on donor availability in patients aged 50-75 with advanced myelodysplastic syndrome.</p> <p>Oral Presentation: 63rd ASH Annual Meeting, Atlanta, GA, December 2021</p>	BMT CTN 1102

Number	Presentation	Protocol Number
132	<p>Geerlinks AV, Scull B, Krupski C, Fleischmann R, Pulsipher MA, Eapen M, Connelly JA, Bollard CM, Pai SY, Duncan CN, Kean LS, Baker KS, Burroughs LS, Andolina JR, Jordan MB, Man TK, Allen CE, and Marsh R. Peri-transplant alemtuzumab levels predict risk of secondary graft failure and inversely impact CXCL9 levels after RIC HCT (A correlative biology study to BMT-CTN 1204 RICHI).</p> <p>Oral Presentation: 63rd ASH Annual Meeting, Atlanta, GA, December 2021</p>	BMT CTN 1204
133	<p>Chung DJ, Shah N, Stroopinsky D, WU J, Bisharat L, Callander NS, Logan BR, Anderson KC, Chodon T, Mohan M, Devine S, Efebera YA, Geller N, Hematti P, Holmberg LA, Howard A, Johnson B, Lazarus HM, Malek E, McCarthy PL, McKenna DH, Mendizabal AM, Munshi NC, O'Donnell L, Rapoport AP, Nooka AK, Reese J, Soiffer RJ, Uhl L, Cheloni G, Karagkouni D, Vlachos I, Young JW, Rosenblatt J, Waller EK, Pasquini MC, Avigan D. 2021 impact of autologous hematopoietic cell transplant (HCT) followed by dendritic cell/myeloma fusion vaccine with lenalidomide maintenance in increasing multiple myeloma (mm) immunity (BMT CTN 1401).</p> <p>Oral Presentation: 63rd ASH Annual Meeting, Atlanta, GA, December 2021</p>	BMT CTN 1401
134	<p>Brooks E, Spahn A, Waldvogel S, Howard A, Bar M, Bratrude B, Chhabra S, Clark W, Das SR, Horowitz MM, Jenq RR, Jones RJ, Levine JE, Logan BR, Murthy HS, Rashidi A, Riches ML, Riwes MM, Sandhu KS, Sung AD, Al Malki MM, Runaas L, Elmariah H, Rezvani AR, Gooptu M, Bolaños-Meade J, Holtan SG, Saber W, Hamadani M, Kean LS, Perales M-A, Bhatt AS. Mi-immune/1801: Lessons from an ongoing, multi-center trial involving biospecimen collection for prospective microbiome and immune profiling in patients undergoing reduced intensity conditioning allogeneic HCT.</p> <p>Poster Presentation: 63rd ASH Annual Meeting, Atlanta, GA, December 2021</p>	BMT CTN 1801
2022		
135	<p>Horowitz MM, Kaur M, Mendizabal A, Chen M, D'Souza A, Foley A, Auletta J, Devine S. Racial and ethnic diversity on Blood and Marrow Transplant Clinical Trials Network (BMT CTN) trials – We can do better.</p> <p>Oral Presentation: Tandem Meetings of ASTCT & CIBMTR, Salt Lake City, UT, April 2022</p>	Network Abstract
136	<p>Riches ML, Hill JA, Martens M, Auletta JJ, Baluch A, Bhavsar K, Brown JW, Dhodapkar MV, DiFronzo N, Howard A, Ibrahim U, Nakamura R, Peyton K, Shahid Z, Sharon E, Spahn A, Toor AA, Waldvogel S, Westervelt P, Young J-AH, Perales M-A, Horowitz, MM. Humoral immunogenicity of SARS-COV-2 vaccination in the first year after hematopoietic cell transplant or chimeric antigen receptor T cell therapy: A CIBMTR and BMT CTN study.</p> <p>Poster Presentation: Tandem Meetings of ASTCT & CIBMTR, Salt Lake City, UT, April 2022</p>	BMT CTN 2101

Number	Presentation	Protocol Number
137	<p>Versluis J, Saber W, Tsai HK, Gibson CJ, Martens MJ, Ramirez A, Logan BR, Horowitz MM, Nakamura R, Cutler C, and Lindsley RC. Mutation analysis in patients with high-risk myelodysplastic syndrome receiving allogeneic stem cell transplantation based on biological donor availability: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) study 1102.</p> <p>Oral Presentation: Tandem Meetings of ASTCT & CIBMTR, Salt Lake City, UT, April 2022</p>	BMT CTN 1102
138	<p>Richardson PG, Jacobus SJ, Weller E, Hassoun H, Lonial S, Raje NS, Medvedova E, McCarthy PL, Libby EN, Voorhees PM, Orlowski RZ, Anderson Jr LD, Hurd DD, Pasquini MC, Masone K, Moreau P, Avet-Loiseau H, Attal M, Anderson KC, Munshi NC. Lenalidomide, bortezomib, and dexamethasone (RVd) ± autologous stem cell transplantation (ASCT) and R maintenance to progression for newly diagnosed multiple myeloma (NDMM): The phase 3 DETERMINATION trial.</p> <p>Oral Presentation (plenary session): ASCO Annual Meeting, Chicago, IL, June 2022</p>	BMT CTN 1304
139	<p>Shaw BE, Kathryn E. Flynn KE, Cusatis R, D'Souza A, Hamilton BK, Horowitz MM, Mattila D, Phelan R, Lee S, Brazauskas R. Incorporating patient reported outcome data into a hematopoietic cell transplant survival calculator.</p> <p>Poster Presentation: ASCO Annual Meeting, Chicago, IL, June 2022</p>	Network Abstract
140	<p>Hourigan CS, Dillon LW, Gui G, Ravindra N, Wong Z, Andrew G, Mukherjee D, El Chaer F, Yoon C, Spellman S, Howard A, Auletta J, Devine SM, Jimenez Jimenez AM, De Lima MJG, Litzow MR, Kebriaei P, Saber W, Weisdorf DJ, Page K. Pre-MEASURE: Multicenter evaluation of the prognostic significance of measurable residual disease testing prior to allogeneic transplantation for adult patients with AML in first remission.</p> <p>Oral Presentation: ASCO Annual Meeting, Chicago, IL, June 2022</p>	BMT CTN 1202
141	<p>Steuten LMG, Bansal A, Li L, Brunstein CG, O'Donnell PV, Eapen M, Sangaralingham LR, Thao V, Roth JA, Wright WE, Ramsey SD. Cost effectiveness of reduced intensity conditioning and transplantation of unrelated umbilical cord blood versus HLA haploidentical related bone marrow for adults with hematologic malignancies.</p> <p>Poster Presentation: ASCO Annual Meeting, Chicago, IL, June 2022</p>	BMT CTN 1101
142	<p>Richardson PG, Jacobus SJ, Weller EA, Hassoun H, Lonial S, Raje NS, Medvedova E, McCarthy PL, Libby EN, Voorhees PM, Orlowski RZ, Anderson Jr LD, Hurd DD, Pasquini MC, Masone K, Moreau P, Avet-Loiseau H, Attal M, Munshi NC, Anderson KC. Phase 3 DETERMINATION trial in newly diagnosed multiple myeloma: Lenalidomide, Bortezomib and dexamethasone (RVD) ± autologous stem cell transplantation and lenalidomide maintenance to progression.</p> <p>Oral Presentation: European Hematology Association Annual Congress. Vienna, Austria, June 2022</p> <p>* Late Breaking Abstract</p>	BMT CTN 1304

Number	Presentation	Protocol Number
143	<p>El Jurdi N, MD, Martens M, Brunstein CG, O'Donnell P, Lee SJ, D'Souza A, Logan B, Hong S, Sandhu K, Shapiro RM, Singh AK, Horowitz MM, Hamilton BK. Quality of life in patients undergoing double umbilical cord blood vs. haploidentical marrow transplantation: A QOL analysis report of BMT CTN 1101.</p> <p>Poster Presentation: 64th ASH Annual Meeting, New Orleans, LA, December 2022</p>	BMT CTN 1101
144	<p>Holtan SG, Hamadani M, Wu J, AL Malki MM, Runaas L, Elmariah H, Rezvani AR, Gooptu M, Larkin KT, Shaffer BC, El Jurdi NH, Loren AW, Melhem Solh M, Hall AC, Alousi AM, Jamy OH, Perales M, Yao JM, Applegate K, Bhatt AS, Kean LS, Efebera YA, Kitko CL, Reshef R, Clark W, DiFronzo NL, Henderson L, Jones RJ, Liefer E, Martens MJ, Horowitz MM, Bolanos-Meade J. Post-transplant cyclophosphamide, tacrolimus, and mycophenolate mofetil as the new standard for graft-versus-host disease (GVHD) prophylaxis in reduced intensity conditioning: Results from Phase III BMT CTN1703.</p> <p>Oral Presentation: 64th ASH Annual Meeting, New Orleans, LA, December 2022</p> <p>* Late Breaking Abstract</p>	BMT CTN 1703
2023		
145	<p>Malek E, Kort J, Metheny L, Fu P, Li G, Hari P, Efebera Y, Qazilbash MH, Giralt S, Krishnan A, Stadtmauer EA, Lazarus H. Impact of visceral obesity on clinical outcome and quality of life for patients with multiple myeloma: A secondary data analysis of STaMINA trial.</p> <p>Poster Presentation: Tandem Meetings of ASTCT & CIBMTR, Orlando, FL, February 2023</p>	BMT CTN 0702
146	<p>Vasu S, Holtan SG, Shimamura A, Burnworth T, Whisenton S, Adams S, Nuechterlein B, Mortier N, Foster J, DiFronzo N, Horowitz MM, Rizzo JD, Foley A. Bringing patient and caregivers voices to the clinical trial chorus: A report from the BMT CTN Patient and Caregiver Advocacy Task Force.</p> <p>Poster Presentation: Tandem Meetings of ASTCT & CIBMTR, Orlando, FL, February 2023</p>	Network Abstract
147	<p>Baiocchi R, Shindiapina P, Pietrzak M, Seweryn M, McLaughlin E, Zhang X, Makowski M, Ahmed E, Pearson R, Kitzler R, Le-Rademacher JG, Little RF, Akpek G, Ayala E, Devine SM, Kaplan LD, Noy A, Papat UR, Hsu J, Morris LE, Mendizabal A, Wachsman W, Williams N, Sharma N, Hofmeister CC, Forman SJ, Navarro WH, Alvarnas JC, Ambinder RF, Malvestutto C, Choe H, Behbehani G, Lozanski G, Blaser B. Update on comparative analysis of immune reconstitution in HIV-positive recipients of allogeneic and autologous stem cell transplant on the BMT CTN 0903/AMC-080 and BMT CTN 0803/AMC-071 trials.</p> <p>Oral Presentation: Tandem Meetings of ASTCT & CIBMTR, Orlando, FL, February 2023</p>	BMT CTN 0903 / 0803
148	<p>Dehn J, Logan B, He N, Shaw BE, Devine S, Vogel J, Erickson C, Ciurea S, Lee SJ, Westervelt P, Srour S, Arai S, Juckett M, Uberti J, Saad A, Hill L, Hogan JW, Hayes-Lattin B, Buck K, Pidala J. A novel donor search and selection algorithm facilitates a comparable incidence of transplant for patients regardless of baseline search prognosis: Report from BMT CTN 1702 trial.</p> <p>Oral Presentation: 49th EBMT Annual Meeting, Paris, France, April 2023</p>	BMT CTN 1702

Number	Presentation	Protocol Number
149	<p>Paczesny S, Martens M, Kou J, Logan B. Machine learning for risk biomarkers of chronic graft-versus-host disease in 936 patients from BMT CTN 0201 & 1202 cohorts.</p> <p>Poster Presentation: 49th EBMT Annual Meeting, Paris, France, April 2023</p>	BMT CTN 0201 / 1202
150	<p>Levis MJ, Hamadani M, Logan B, Jones R, Singh AK, Litzow M, Wingard JR, Papadopoulos EB, Perl AE, Soiffer R, Ustun C, Ueda Oshima M, Uy G, Waller EK, Vasu S, Solh M, Mishra A, Muffly L, Kim H, Stelljes M, Najima Y, Onozawa M, Thomson K, Nagler A, Wei A, Marcucci G, Geller NL, Hasabou N, Delgado D, Rosales M, Hill J, Gill S, Nuthethi R, King D, Wittsack H, Mendizabal A, Devine S, Horowitz M, Chen Y. BMT-CTN 1506 (MORPHO): A randomized trial of the FLT3 inhibitor gilteritinib as posttransplant maintenance for FLT3-ITD AML.</p> <p>Oral presentation: European Hematology Association Annual Congress, Frankfurt Germany, June 2023</p> <p>*Late Breaking Abstract</p>	BMT CTN 1506
151	<p>Eapen M, Antin J, Tolar J, Arai S, Horowitz M, Kou J, Leifere E, McCarty JM, Nakamura R, Pulsipher MA, Horowitz MM, Deeg HJ. Long-term outcomes after unrelated marrow transplantation for aplastic anemia with optimized cyclophosphamide dose (BMT CTN 0301).</p> <p>Oral Presentation: 65th ASH Annual Meeting, San Diego, CA, December 2023</p>	BMT CTN 0301
152	<p>Artz A, Logan BR, Saber W, Geller N, Bellach A, Kou J, Wood W, McCarty JM, Knight TG, Runaas L, Johnston L, Walston J, Nakamura R, Schuler T, Mishra A, Uberti J, Dahi PB, Saultz JN, McCurdy SR, Morris L, Imus P, Hogan WJ, Nadiminti K, Bhatt VR, Mattila D, Protz B, Devine SM, Horowitz MM, Sorrow M. The composite health risk assessment model (CHARM) to predict 1-year non-relapse mortality (NRM) among older recipients of allogeneic transplantation: A prospective BMT-CTN clinical trial 1704.</p> <p>Oral Presentation: 65th ASH Annual Meeting, San Diego, CA, December 2023</p>	BMT CTN 1704
153	<p>Holtan SG, Martens MJ, Al Malki MM, Efebera YA, Kitko CL, Reshef R, Rezvani AR, Shaffer BC, Solh MM, Yao JM, Runaas L, Elmariah H, Larkin KT, El Jurdi N, Goptu M, Loren AW, Hall AC, Alousi A, Jamy O, Clark W, Kean L, Bhatt AS, Perales MA, Applegate K, Wu J, Liefer E, DiFronzo N, Jones RJ, Horowitz, MM, Mattila D, Hamadani M, Bolanos-Meade J. Patient-reported outcomes of BMT CTN 1703: A randomized phase III study for GVHD prophylaxis - A quality of life evaluation.</p> <p>Oral Presentation: 65th ASH Annual Meeting, San Diego, CA, December 2023</p>	BMT CTN 1703
154	<p>Levis MJ, Hamadani M, Logan BR, Jones RJ, Singh AK, Litzow MR, Wingard JR, Papadopoulos EB, Perl A, Soiffer RJ, Ustun C, Ueda Oshima M, Uy GL, Waller EK, Vasu S, Solh MM, Mishra A, Muffly LS, Kim H, Stelljes M, Najima Y, Onozawa M, Thomson K, Nagler A, Wei AH, Marcucci G, Hasabou N, Rosales M, Hill J, Gill SC, Nuthethi R, King D, Wittsack H, Mendizabel A, Devine SM, Horowitz MM, Chen Y. Post-hoc analysis of measurable residual disease from BMT-CTN 1506/MORPHO: FLT3-ITD variant allele frequency and survival are highly correlated.</p> <p>Oral Presentation: 65th ASH Annual Meeting, San Diego, CA, December 2023</p>	BMT CTN 1506

155	<p>Andreadis C, Bobek O, HsiED, Fenske TS, Geyer SM, Stiff PJ, Hill BT, Horwitz M, Khimani F, Little RF, Dinner SN, Friedberg JW, Kahl BS, Perales MA, Devine SM, Leonard JP, Bartlett NL. Ibrutinib added to standard conditioning and as consolidation therapy following autologous hematopoietic stem cell transplantation (AutoHCT) for relapsed/refractory activated-B-cell subtype diffuse large B-cell lymphoma (ABC-DLBCL): Primary analysis of the US intergroup double-blind randomized phase III study alliance 051301/BMT-CTN 1201.</p> <p>Oral Presentation: 65th ASH Annual Meeting, San Diego, CA, December 2023</p>	BMT CTN 1201
156	<p>Gadalla SM, Katki H, Lai T, Dagnall C, Bupp C, Hutchinson A, Anderson J, Mendez K, Spellman SR, Stewart V, Savage SA, Lee SL, Levine J, Saber W, Aviv A. Donor hematopoietic cell telomere length and magnitude of post-HCT shortening predict survival in early stage leukemia and myelodysplastic syndrome.</p> <p>Oral Presentation: 65th ASH Annual Meeting, San Diego, CA, December 2023</p>	BMT CTN 1202
157	<p>Lakkaraja M, Mauguen A, Hosszu KK, McAvoy D, Stewart V, Schmidt G, Levine J, Perales MA, Giralto SA, Baker KS, Boelens JJ. Rabbit antithymocyte (rATG) exposure and outcomes after hematopoietic cell transplantation: A real world experience from BMT CTN 1202.</p> <p>Oral Presentation: 65th ASH Annual Meeting, San Diego, CA, December 2023</p>	BMT CTN 1202
158	<p>Su CT, Saber W, Bansal A, Li L, Nakamura R, Cutler C, Scott BL, Sangaralingham LR, Thao V, Roth J, Wright W, Steuten L, Mattila D, Ramsey SD. Out-of-pocket costs and financial hardship among participants of the BMT CTN 1102 Study.</p> <p>Oral Presentation: 65th ASH Annual Meeting, San Diego, CA, December 2023</p>	BMT CTN 1102
159	<p>Kean L, Siegel SJ, Schmalz JT, Bien SA, Scheffey D, Sanders C, Robins H, Applegate K, Bar M, Chhabra S, Choi SW, Clark W, Das SR, Jenq RR, Jones RJ, Levine J, Logan BR, Murthy HS, Rashidi A, Riches ML, Saber W, Sandhu KS, Sung AD, Larkin K, Al Malki MM, Goptu M, Elmariah H, Alousi A, Runaas L, Shaffer BC, Rezvani AR, El Jurdi N, Loren AW, Horowitz MM, Bolanos-Meade J, Holtan SG, Bhatt AS, Perales MA, DeWolf S. Large-scale post-transplant TCR deep sequencing reveals a major T cell diversity bottleneck with post-transplant cyclophosphamide with implications for both efficacy and toxicity: Results of the BMT CTN 1801 study.</p> <p>Oral Presentation: 65th ASH Annual Meeting, San Diego, CA, December 2023</p>	BMT CTN 1801
160	<p>Martens MJ, Kou J, Logan BR, Paczesny S. Machine learning validates risk biomarkers of chronic graft-versus-host disease in 936 patients from BMT CTN 0201 & 1202 cohorts.</p> <p>Oral Presentation: 65th ASH Annual Meeting, San Diego, CA, December 2023</p>	BMT CTN 0201 / BMT CTN 1202
161	<p>Kassim AA, Walters MC, Eapen M, Smith M, Solh MM, McKinney C, Nieder M, Ross M, Kent M, Abusin G, Mallhi KK, Silva JG, Shaughnessy P, Kanter J, Haines H, Farah RJ, Khaled Y, Abraham A, Bollard CM, Cooke KR, de La Fuente J, Hanna R, Horowitz MM, Jordan LC, Krishnamurti L, Leifer E, Mahadeo KM, Shenoy S, Ritzau N, DeBaun MR, Brodsky RA. Reduced intensity haploidentical bone marrow transplantation in adults with severe sickle cell disease: BMT CTN 1507.</p> <p>Oral Presentation: 65th ASH Annual Meeting, San Diego, CA, December 2023</p> <p>* Late Breaking Abstract</p>	BMT CTN 1507

2024		
162	<p>Hamilton BK, Levis MJ, Pandya BJ, Elsouda D, Logan B, Chen Y, Hamadani M, Ueda M, Perl AE, Singh AK, Soiffer RJ, Litzow MR, Ustun C, Rosales M, Ivanescu C, Cella D, Hasabou N, Corredoira L, Pestana C, Horowitz MM. Health-related quality of life with gilteritinib versus placebo post-transplant maintenance for FLT3-ITD+ acute myeloid leukemia (AML): A quality of life analysis from BMT CTN 1506.</p> <p>Oral Presentation: Tandem Meetings of ASTCT & CIBMTR, San Antonio, TX, February 2024</p>	BMT CTN 1506
163	<p>Hill JA, Martens MJ, Young JH, Bhavsar K, Kou J, Chen M, Lee LW, Baluch A, Dhodapkar MV, Nakamura R, Peyton K, Shahid Z, Armistead PM, Westervelt P, McCarty JM, McGuirk JP, Hamadani M, DeWolf S, Hosszu K, Sharon E, Spahn A, Toor AA, Waldvogel S, Greenberger LM, Auletta JJ, Horowitz MM, Riches ML, Perales MA, MD27, Sars-Cov-2 vaccination in the first year after hematopoietic cell transplant or chimeric antigen receptor T cell therapy: A CIBMTR and BMT CTN Study.</p> <p>Oral Presentation: Tandem Meetings of ASTCT & CIBMTR, San Antonio, TX, February 2024</p>	BMT CTN 2101
164	<p>Pasquini MC, Soiffer R, Logan B, Kaur M, Devine SM, Geller N, Giralt SA, Heslop HE, Horowitz MM, Litzow MR, Mendizabal A, Muffly LS, Nemecek E, O'Donnell LC, Schetelig J, Shune L, Solomon SR, Vasu S, Ho VT, Perales MA, Luznik L. Calcineurin inhibitor-free graft-versus-host disease (GVHD) prophylaxis in hematopoietic cell transplantation (HCT) with myeloablative conditioning regimens (MAC) and HLA-matched donors: Long term follow up of BMT CTN 1301 progress II trial.</p> <p>Oral Presentation: Tandem Meetings of ASTCT & CIBMTR, San Antonio, TX, February 2024</p>	BMT CTN 1301
165	<p>Pidala JA, Logan B, He N, Lee SJ, Ciurea SO, Devine SM, Shaw BE, Vogel J, Erickson C, Bashey A, Doyle J, DiFronzo N, Farhadfar N, Grunwald MR, Hayes-Lattin B, Henderson L, Hogan WJ, Horowitz MM, Leifer E, Symons H, Pusic I, Srour SA, Arai S, Juckett M, Howard DS, Uberti J, Hill LC, Vasu S, Dehn J. Donor Search and selection strategy to facilitate comparable transplant rates across donor search prognosis groups: A report from the BMT CTN 1702 trial.</p> <p>Oral Presentation: Tandem Meetings of ASTCT & CIBMTR, San Antonio, TX, February 2024</p>	BMT CTN 1702
166	<p>Lakkaraja M, Mauguen A, McAvoy D, Hosszu K, Singh KH, Vidal EH, Stewart V, Schmidt G, Levine JE, Perales MA, Giralt SA, Baker KS, Boelens JJ. Discovery proteomics for analytes to predict outcomes after hematopoietic stem cell transplantation: A real world experience from BMT-CTN-1202.</p> <p>Poster Presentation: Tandem Meetings of ASTCT & CIBMTR, San Antonio, TX, February 2024</p>	BMT CTN 1202
167	<p>Bhasin-Chhabra B, M.D., Wang T, Levine JE, Shenoy S, Perales MA, Bashey A, Raff H, Saber W. Soluble urokinase-type plasminogen activator receptor (suPAR) as a biomarker of acute kidney injury requiring dialysis (AKI-D) in patients undergoing allogeneic hematopoietic cell transplantation (HCT): Results from the Blood and Marrow Transplant Clinical Trials Network 1202 study.</p> <p>Poster Presentation: Tandem Meetings of ASTCT & CIBMTR, San Antonio, TX, February 2024</p>	BMT CTN 1202

168	<p>Hahn TE, Zhu Q, Herr M, Liang S, Hu Q, Singh PK, Gao X, Pasquini MC, Leonard JT, Rosko A, Bayer RL, Krishnan A, Stadtmauer EA, Maziarz RT, McCarthy PL, Hahn TE. Discovery of an inherited variant associated with susceptibility to secondary acute lymphoblastic leukemia (ALL) after lenalidomide maintenance and autologous HCT for multiple myeloma (MM).</p> <p>Poster Presentation: Tandem Meetings of ASTCT & CIBMTR, San Antonio, TX, February 2024</p>	BMT CTN 0702
-----	---	--------------